PMID- 36911734 OWN - NLM STAT- MEDLINE DCOM- 20230314 LR - 20230327 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - The association between genetic variants at 3'-UTR and 5'-URR of HLA-G gene and the clinical outcomes of patients with leukemia receiving hematopoietic stem cell transplantation. PG - 1093514 LID - 10.3389/fimmu.2023.1093514 [doi] LID - 1093514 AB - In addition to the classical human leukocyte antigen (HLA) genes, the outcomes of post-hematopoietic stem cell transplantation (HSCT) are associated with human leukocyte antigen (HLA)-related genes and non-HLA genes involved in immune regulation. HLA-G gene plays an important role in immune tolerance, assisting immune escape of tumor cells, and decrease of transplant rejection. In this study, we explored the association of genetic variants at the 3'-untranslated region (3'-UTR) and 5'-upstream regulatory region (5'-URR) of HLA-G gene with the adverse outcomes of patients with leukemia receiving HSCT. The genomic DNAs of 164 patients who had acute leukemia and received HSCT were collected for analysis. Nine single nucleotide polymorphisms (SNPs) and six haplotypes in the 3'-UTR and 27 SNPs and 6 haplotypes in the 5'-URR were selected to investigate their relationship with the development of adverse outcomes for patients receiving HSCT, including mortality, relapse, and graft-versus-host disease. Our results revealed that two SNPs (rs371194629 and rs9380142) and one haplotype (UTR-3) located in the 3'-UTR and two SNPs (rs3823321 and rs1736934) and one haplotype (G0104a) located in the 5'-URR of HLA-G were associated with the occurrence of chronic GVHD or development of any forms of GVHD. No SNP was found to associate with the occurrence of mortality and relapse for patients receiving HSCT. These SNPs and haplotypes may play important roles in regulating immune tolerance of allografts post-HSCT that can be used to predict the risk of poor outcomes after receiving HSCT and giving preventive treatment to patients on time. CI - Copyright (c) 2023 Chen, Wang, Hour, Lin, Hsu, Wang and Tseng. FAU - Chen, Ding-Ping AU - Chen DP AD - Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. AD - Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Wang, Po-Nan AU - Wang PN AD - Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Hour, Ai-Ling AU - Hour AL AD - Department of Life Science, Fu Jen Catholic University, New Taipei City, Taiwan. FAU - Lin, Wei-Tzu AU - Lin WT AD - Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Hsu, Fang-Ping AU - Hsu FP AD - Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Wang, Wei-Ting AU - Wang WT AD - Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Tseng, Ching-Ping AU - Tseng CP AD - Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. AD - Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan. AD - Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230223 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (HLA-G Antigens) RN - 0 (Histocompatibility Antigens Class II) SB - IM MH - Humans MH - HLA-G Antigens/genetics MH - *Graft vs Host Disease MH - *Leukemia, Myeloid, Acute/genetics MH - Histocompatibility Antigens Class II MH - *Hematopoietic Stem Cell Transplantation/adverse effects MH - Recurrence PMC - PMC9995383 OTO - NOTNLM OT - graft versus host disease (GVHD) OT - haplotype OT - hematopoietic stem cell transplantation (HSCT) OT - human leukocyte antigen-G (HLA-G) OT - single nucleotide polymorphism (SNP) COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/03/14 06:00 MHDA- 2023/03/15 06:00 PMCR- 2023/01/01 CRDT- 2023/03/13 04:29 PHST- 2022/11/09 00:00 [received] PHST- 2023/02/02 00:00 [accepted] PHST- 2023/03/13 04:29 [entrez] PHST- 2023/03/14 06:00 [pubmed] PHST- 2023/03/15 06:00 [medline] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1093514 [doi] PST - epublish SO - Front Immunol. 2023 Feb 23;14:1093514. doi: 10.3389/fimmu.2023.1093514. eCollection 2023.